FDA gives fast track to promising kidney cancer drug

04/6/2004 | Medscape (free registration)

A new drug designed for treatment of advanced kidney cancer has received the OK for placement on fast-track status for FDA approval. The drug, known as BAY 43-9006, prevents tumor growth by two means -- antiangiogenesis and inhibition of tumor cell proliferation -- and its fast-track status will allow its makers, Onyx Pharmaceuticals and a unit of German drugmaker Bayer AG, to submit data as it becomes available instead of waiting until clinical studies are complete.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations